2026-09-26
notable
Enrollment closed, study ongoing
Primary completion pushed: 2026-08-01 → 2026-12-31
Completion pushed: 2026-08-01 → 2026-12-31
2026-05-26
minor
Study Status, Oversight v4
Primary completion date2026-04-01→2026-08-01
Completion date2026-04-01→2026-08-01
2025-07-31
minor
Study Status, Oversight, Study Description, Eligibility v3
Primary completion date2025-04-01→2026-04-01
Completion date2025-04-01→2026-04-01
Eligibility criteria-279 characters
Inclusion Criteria:
i) Experimental group (participants with a diagnosis of schizophrenia spectrum disorder):
Antipsychotic naïve or antipsychotic treatment for equal to or less than 3 weeks within the past 3 months
(Medications can be confirmed via CAMH chart review).
Participants do not need to remain off of antipsychotics for the duration of the study.
17-45 years
both sexes;
Patients with first-episode schizoph [...] confirmed via CAMH chart review).
BMI under or equal to 27
Right-handed
ii) Control group (healthy controls):
17-45 years of age
sex-,
hand dominance (right-handed) -and
body mass i [...] [...]
Study description-66 characters
[...] nsulin action is a feature of SCZ.
The study examines young antipsychotic-naïve/free SCZ patients to minimize medication-related confounds.
Insulin (160 IU; shown to be safe and effective previously [...]
2024-08-19
minor
Study Status v2
Re-verified, no change to tracked fields
2024-01-11
notable
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Study sites0→1
2023-02-28
minor
Original filing